Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study finds potential way to improve cancer immunotherapy

05.09.2003


Drugs that contain antibodies are a standard part of therapy for many cancers, but these antibodies do not always work. A finding by researchers with the Holden Comprehensive Cancer Center at the University of Iowa may help make the antibodies more effective by boosting the power of white blood cells, which play a role in fighting cancer.



One way that antibodies ideally function is to stick to cancer cells and signal various types of white blood cells to kill the cancer cells. The UI Holden Center team and colleagues used mouse cell lines that mimic human conditions to learn how different types of white blood cells work with antibodies and contribute to killing cancer cells. The team used different classes of an immune stimulant known as CpG ODN (CpG oligodeoxynucleotide) to encourage different types of white blood cells, either separately or together, to work with antibodies to kill cancer.

The new information could help doctors make antibodies more effective by providing a way to gear up specific types of white blood cells -- natural killer cells and granulocytes -- at the same time that patients receive a dose of anti-cancer antibodies, said George Weiner, M.D., UI professor of internal medicine, director of the Holden Comprehensive Cancer Center and principal investigator for the study. The findings appear in the Sept. 1 issue of the journal Cancer Research.


"Previous research suggested that different white blood cells can kill cancer cells," Weiner said. "We found that by selecting other agents as stimulants, we can specially direct one type or another of white blood cells to do the killing. It’s an extra measure of control for the white blood cells that you specifically want to activate to destroy the cancer cells."

Weiner said the finding potentially could lead to improved therapies for patients. The UI currently is evaluating this approach in clinical trials.

Monoclonal antibodies currently used in cancer therapies include rituximab (Rituxan) for certain types of non-Hodgkin’s lymphoma and trastuzumab (Herceptin) for breast cancer.

People do not normally have these antibodies in their system. The cancer-fighting versions are based on natural antibodies and designed to react with cancer cells, Weiner said. With cancers, the immune system fails to recognize tumors as invaders -- that is where drugs can step in and make a difference.

"Using antibodies is a way of taking the immune system and redirecting it toward killing the cancer," Weiner said.

Non-Hodgkin’s lymphoma is cancer of the lymphatic system, which normally fights infection. The lymphatic system includes lymph nodes and parts of the body that include lymphatic tissues: the spleen, thymus gland, bone marrow, adenoids and tonsils.


###
Contributors to the study included investigators at the University Medical Center Utrecht in the Netherlands.

Funding for the study included a Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI). For information on that grant, visit http://www.uiowa.edu/~ournews/2002/september/0918SPORE.html. The study also included support from Coley Pharmaceutical Group. Weiner serves as a consultant for Coley.

The Holden Comprehensive Cancer Center is Iowa’s only National Cancer Institute (NCI)-designated comprehensive cancer center. NCI-designated comprehensive cancer centers are recognized as the leaders in developing new approaches to cancer prevention and cancer care, conducting leading edge research and educating the public about cancer.

University of Iowa Health Care describes the partnership between the UI Roy J. and Lucille A. Carver College of Medicine and UI Hospitals and Clinics and the patient care, medical education and research programs and services they provide. Visit UI Health Care online at www.uihealthcare.com.

Becky Soglin | EurekAlert!
Further information:
http://www.uiowa.edu/~ournews/2002/september/0918SPORE.html
http://www.uihealthcare.com

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

Im Focus: Optoelectronic Inline Measurement – Accurate to the Nanometer

Germany counts high-precision manufacturing processes among its advantages as a location. It’s not just the aerospace and automotive industries that require almost waste-free, high-precision manufacturing to provide an efficient way of testing the shape and orientation tolerances of products. Since current inline measurement technology not yet provides the required accuracy, the Fraunhofer Institute for Laser Technology ILT is collaborating with four renowned industry partners in the INSPIRE project to develop inline sensors with a new accuracy class. Funded by the German Federal Ministry of Education and Research (BMBF), the project is scheduled to run until the end of 2019.

New Manufacturing Technologies for New Products

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

A new technique isolates neuronal activity during memory consolidation

22.06.2017 | Life Sciences

Plant inspiration could lead to flexible electronics

22.06.2017 | Materials Sciences

A rhodium-based catalyst for making organosilicon using less precious metal

22.06.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>